Company profile
Kura Oncology, Inc. logo

Kura Oncology, Inc.

Pipeline4 assets

  • ZiftomenibKO-539 / KOMZIFTI / Menin-KMT2A/MLL interaction / Small molecule / Hematologic Malignancies
    R/R NPM1-mutated AMLNewly Diagnosed AMLFLT3-mutated AML
  • DarlifarnibKO-2806 / Farnesyl transferase / Small molecule / Oncology
    Clear cell renal cell carcinoma (ccRCC)Solid tumors
  • TipifarnibFarnesyl transferase / Small molecule / Oncology
    HRAS-mutant Head and Neck Squamous Cell Carcinoma (HNSCC)PIK3CA-dependent HNSCC
  • KO-7246KO-7246 / Menin / Small molecule / Cardiometabolic
    DiabetesCardiometabolic disease

Latest news17 items

All news

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib’s potential as a precision combination agent across

Presentation / Abstract • Phase 1ASCO presentation release Sat, May 30, 2026, 5:00 AM PT

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) today announced its participation in the TD Cowen 7 th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Kura management is scheduled to participate in a virtual fireside chat at 1:30 p.m. ET / 10:30 a.m.

Kura Oncology Reports First Quarter 2026 Financial Results

– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum – – Broad and rapid payer access achieved, with >

Presentation / Abstract • Phase 1ASCO presentation Fri, May 29, 2026

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Durable responses with median duration of CRc not reached in NPM1-m patients at ~15 months median

Presentation / Abstract • Phase 1EHA abstract release Tue, May 12, 2026, 9:30 AM ET

Kura Oncology to Report First Quarter 2026 Financial Results

SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2026 financial results after the close of U.S.

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on May 1, 2026, the Compensation Committee of the Company’s Board

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2026, the Compensation Committee of the Company’s

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 2, 2026, the Compensation Committee of the Company’s

Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting ongoing development plans targeting up to 50% of AML patients – – Orange Book listing of

Trial Start • Phase 1

Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, March

Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the following investor conferences: TD Cowen Health Care

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on February 2, 2026, the Compensation Committee of the Company’s

Kura Oncology, Inc. • Endpoint Arena